S
Stephanie Lheureux
Researcher at Princess Margaret Cancer Centre
Publications - 112
Citations - 1537
Stephanie Lheureux is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 15, co-authored 112 publications receiving 846 citations. Previous affiliations of Stephanie Lheureux include University Health Network & University of Toronto.
Papers
More filters
Journal ArticleDOI
FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
Nicolas Aide,Rodney J. Hicks,Rodney J. Hicks,Christophe Le Tourneau,Christophe Le Tourneau,Stephanie Lheureux,Stefano Fanti,Egesta Lopci +7 more
TL;DR: A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects withFDG PET based on published data and experts’ experience.
Journal ArticleDOI
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux,Mihaela C. Cristea,Jeff Bruce,Swati Garg,Michael Cabanero,Gina Mantia-Smaldone,Alexander B. Olawaiye,Susan Ellard,Johanne I Weberpals,Andrea E. Wahner Hendrickson,Gini F. Fleming,Stephen Welch,Neesha C. Dhani,Tracy Stockley,Prisni Rath,Katherine Karakasis,Gemma N Jones,Suzanne Jenkins,Jaime Rodriguez-Canales,Michael Tracy,Qian Tan,Valerie Bowering,Smitha Udagani,Lisa Wang,Charles A. Kunos,Eric Chen,Trevor J. Pugh,Amit M. Oza +27 more
TL;DR: In this paper, the Wee1 inhibitor combined with gemcitabine was evaluated in patients with high-grade serous ovarian cancer, a TP53-mutated tumour type with high replication stress.
Journal ArticleDOI
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux,Stephanie Lheureux,Ana Oaknin,Swati Garg,Jeff Bruce,Ainhoa Madariaga,Neesha C. Dhani,Neesha C. Dhani,Valerie Bowering,Justin White,Sarah Accardi,Qian Tan,Marsela Braunstein,Katherine Karakasis,Iulia Cirlan,Stephanie Pedersen,Tiantiam Li,Lorena Fariñas-Madrid,Yeh Chen Lee,Zhihui Amy Liu,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Amit M. Oza,Amit M. Oza +24 more
TL;DR: This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis and the activity of cediranib–olaparib varied according to the PARPi resistance mechanism.
Journal ArticleDOI
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
Stephanie Lheureux,C. Denoyelle,Pamela S. Ohashi,J.S. de Bono,Felix M. Mottaghy,Felix M. Mottaghy +5 more
TL;DR: The concept of targeted therapy in cancer and the challenges that exist for molecular imaging in cancer care are focused on.
Journal ArticleDOI
FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study.
Marie Plante,Nienke E. van Trommel,Stephanie Lheureux,Amit M. Oza,Lisa Wang,Karolina Sikorska,Sarah E. Ferguson,Kathy Han,Frédéric Amant,Frédéric Amant +9 more
TL;DR: This study aims to evaluate the feasibility of preserving fertility in pre-menopausal women diagnosed with stage International Federation of Gynecology and Obstetrics IB2, 2–4 cm cervical cancer by assessing the rate of functional uterus defined as successful fertility-sparing surgery and no adjuvant therapy.